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Abstract
Background Understanding the characteristics of
smokers who are successful in quitting may help to increase smoking cessation rates.
Purpose To examine heterogeneity in cessation outcome at 6 months following smoking cessation behavioral counseling with or without weight management
counseling.
Methods 2,540 smokers were recruited from a large
quitline provider and then randomized to receive proactive smoking cessation behavioral counseling without
or with two versions of weight management counseling.
A Classification and Regression Tree (CART) analysis
was conducted to identify the individual pretreatment
and treatment characteristics of groups of smokers
with different quitting success (as measured by point
prevalence of self-reported smoking of any amount at
6 months).
Results CART analysis identified 10 subgroups ranging
from 25.5% to 70.2% abstinent. The splits in the CART
tree involved: the total number of counseling and control calls received, whether a smoking cessation pharmacotherapy was used, and baseline measures of cigarettes
per day, confidence in quitting, expectation that the
study would help the participant quit smoking, the
motivation to quit, exercise minutes per week, anxiety,
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and lack of interest or pleasure in doing things. Costs
per quitter ranged from a low of $US270 to a high of
$US630. Specific treatment recommendations are made
for each group.
Conclusions These results indicate the presence of a substantial variation in abstinence following treatment, and
that the total extent of contact via counseling calls of
any type and baseline characteristics, rather than assigned treatment, were most important to subgroup
membership and abstinence. Tailored treatments to subgroups who are at high risk for smoking following a quit
attempt could increase successful smoking cessation.
Keywords CART ∙ Smoking cessation ∙ Weight management ∙ Cost per quitter ∙ Intentions ∙ Abstinence ∙
Relapse

Introduction
Research shows that two-thirds of smokers calling
quitlines are overweight or obese, and two-thirds are
concerned that quitting smoking will cause them to gain
weight [1]. Understanding how to optimize both smoking
cessation and weight gain reduction in the quitline setting is an important public health priority. Several previous studies have been conducted to determine the
impact on tobacco abstinence and suppression of excess
weight gain of adding weight management intervention
to tobacco cessation counseling [2–4]. Those studies motivated the clinical study (the Best Quit Study or BQS)
[5], providing data for this analysis. Here, we address the
cessation outcomes of that study.
The BQS study tested the impact on abstinence and
weight control of adding an evidence-based weight
control intervention simultaneously with or sequentially after cessation treatment delivered via telephone
quitlines. Results of the randomized controlled trial
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indicated that multiply imputed abstinence rates were
lower for simultaneous (40.3%) than sequential (48.3%)
and control (44.9%) participants at 6 months (p < .05)
and 12 months (40.7% versus 46.3% and 46.0%, respectively, p < .05). However, completers showed no differences in abstinence at 6 or 12 months. Observed and
multiply imputed weight gain at 6 and 12 months was
minimal and not different among treatment groups [5].
The treatments showed limited average weight management effects, at least partly because individuals assigned
to each treatment group differed substantially in their
outcomes. The goal of the current paper is to identify
characteristics of smokers who have low cessation rates
at 6 months (the time period closest to the treatments
received) and to compare their baseline and treatment
characteristics with those who are successful at quitting.
This can improve our understanding of predictors of
the heterogeneity of quit outcomes and help identify
groups who may need additional or different support
with quitting.

Methods
Recruitment, Screening, and Randomization
The Best Quit intervention study is described in detail
by Bush et al. [5–7] and summarized below. This study
was implemented by Alere Wellbeing, a provider of tobacco quitline services and a phone/web-based weight
management program. Participants were recruited from
three state quitlines and 10 commercial (workplace)
quitlines. Candidates were eligible if they were 18 years
of age and older, had a body mass index (BMI) ≥18.5,
smoked at least 10 cigarettes per day (CPD), wanted to
quit smoking within 30 days, and could speak and read
English. A total of 2,528 individuals were found eligible
and randomly allocated to one of three treatment groups
(cessation alone, simultaneous weight management, or
sequential weight management). Process and outcome
data at 6 and 12 months were collected via web survey,
phone, and mail.
Intervention and Control Arm Procedures
Smokers in all study arms received 10 coaching calls plus
additional calls if requested. Coaches made several attempts per day over five different days to reach study participants to complete each of their 10 planned counseling
sessions. Treatment was participant focused, so the duration of each call varied by participant needs but followed
the general protocol of 20 min for Call 1 and 10 min for
remaining calls. The first “inbound” call was initiated by
the smoker; “proactive” calls 2–10 were initiated by the

coach. All participants could phone in to the quitline for
additional support at any time. The cessation-only treatment group (control) received five standard quitline cessation calls followed by five healthy living program calls.
The simultaneous group received five calls that combined
cessation and weight management content followed by
five healthy living program calls. The sequential group
received five standard quitline cessation calls followed
by five weight management calls. The healthy living calls
acted as a contact control to equalize number of contacts
with a coach across all three groups. For the simultaneous
group, during the second call, a quitline coach completed
the standard tobacco content and then transferred the
participant to a registered dietician (RD).
Tobacco Cessation Treatment
The cessation treatment for all groups involved the Quit
for Life (QFL) program that includes five telephone
counseling sessions with a coach plus unlimited callins to the quitline for help at any time, a website with
support materials, a mailed Quit Kit, and free nicotine
replacement therapy (NRT) in the form of patch, gum,
and/or lozenge (0–8 weeks) depending on the contract
for providing smoking cessation services and appropriateness based on the participant’s medical condition.
Weight Management Treatment
The weight management program for the simultaneous and
sequential treatment groups involved five counseling calls
offered by coaches and RDs, mailed materials, and access
to a web-based weight management program with on-line
tracking forms, goal setting, and educational components.
Coaches encouraged participants to set diet, physical activity,
and weight goals, regularly self-monitor their weight, dietary
intake (e.g., calories), stress, and physical activity level. The
second call of the weight management intervention (Call 2
for simultaneous, Call 8 for sequential) was delivered by an
RD and covered calorie reduction strategies and the rationale
for why and how to reduce caloric intake. Dietary, physical
activity, and behavior change intervention content came from
interventions proven to be efficacious in producing weight loss
[8–11]. The physical activity component focused on moving
more and sitting less. A stress reduction component focused
on identifying and controlling stressful situations, finding and
practicing coping skills, and monitoring progress.
Healthy Living Program Calls
The five healthy living (control) calls addressed sun protection, flu prevention, pedestrian safety, disaster preparedness, and home energy savings. During these calls,
coaches did not discuss tobacco or weight.
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Coaches
Interventions were delivered by experienced coaches
and RDs. Coach training included reviewing the treatment manual, listening to tape recorded “mock” calls
and practicing the intervention content via role-plays.
Coaches covered specific intervention topics visible to
them via their on-line coaching application.
Data Collection
Participants’ demographic, smoking, and weight characteristics were assessed by self-report surveys administered at baseline by a quitline registration agent and a
coach (depending on the item being assessed) and at 6
and 12 months postrandomization by the survey team
who were blinded to treatment arm. Participants could
earn up to $110 for completing the three surveys ($30 for
baseline; $35 for the 6 month survey, $35 for the 12 month
survey, and $10 for early completion of the 12 month
web survey). Two weeks prior to the 6 and 12 month
target dates, participants were sent an email with a link
to the survey. Survey nonresponders were sent reminder
emails and those still nonresponsive were contacted by
phone. Survey staff attempted telephone outreach for at
least 11 days and left several voice messages asking the
participant to call the quitline. Individuals who still did
not respond were sent a mailed copy of the survey with
a stamped return envelope. Those who failed to return
the mailed survey within 2 weeks were sent a short form
survey asking only four questions (satisfaction, tobacco
status, CPD, and current weight). The envelope stated
that compensation was enclosed (a $2 bill was enclosed
with the survey). In addition to self-reported data, call
completion data were collected by Alere and included
type and number of counseling calls completed (scheduled and participant-initiated calls).
Study Measures
Screening data collected by a registration agent when a
smoker called into the quitline included standard demographic and tobacco use questions (e.g., name/address/
phone numbers, self-reported age, gender, and chronic
disease status [asthma, pulmonary disease, heart disease,
or diabetes) plus study-specific questions (CPD, height,
weight, history of eating disorder, weight loss surgery, access to internet; reachable for next 6 months; and willing
to take additional five counseling calls). Baseline data
collected by a coach prior to randomization included
questions about race, ethnicity, education, marital status,
depression/anxiety, whether dieting, level of concern
about weight gains after quitting, and confidence about
avoiding weight gain while staying quit. Content of the
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6 month and 12 month surveys included self-reported:
duration of “no puff ” abstinence, type and amount of
tobacco used, cessation medications used, symptoms of
depression or anxiety, satisfaction with the quitline, satisfaction with the study, current weight, changes in diet,
eating patterns, physical activity level, and use of an activity monitor. A subset of these measures was used for
the current paper.
The measures used for this paper are in line with the
theoretical underpinnings of the study interventions and
have been shown to be related to treatment outcomes.
In accordance with the treatment model (social cognitive theory) used for this study, treatment focused on
personal, environmental, social, and behavioral factors,
which influence each other in ways shown to change
health behavior [12]. Within this theoretical model are
concepts that have an effect on motivation and predict
cessation and/or weight outcomes including: anticipated
outcomes of a behavior (expectations) [4, 13] and confidence in one’s ability to take action (self-efficacy) [12].
Specifically, we included variables known to predict
health behaviors of tobacco cessation and /or weight
control. These include personal factors such as lower
age, lower education, and socio-economic status, being
male, greater nicotine dependence measured by CPD,
and weight-related factors (BMI, weight concerns,
dieting behaviors). Motivation for quitting tobacco [14]
and self-efficacy for smoking abstinence and confidence
in avoiding weight gain are also predictive of health behavior changes [15–17].
Statistical Analysis
CART analysis was used to separate individuals into
groups that exhibited different 6 month observed abstinence. CART is a form of decision tree learning commonly
used in data mining [18]. CART recursively splits participants into subgroups based on a collection of variables
that potentially predict the outcome of interest (which
in this study is abstinence at 6 months). Predictors are
selected based on their ability to optimally divide patients
into smaller homogeneous subgroups, with each split
improving homogeneity [19]. CART creates trees that are
easy for clinicians to interpret [20, 21]. It is particularly
useful in identifying subgroups of individuals because it:
(a) does not assume that predictors are linearly related
to the outcome of interest; (b) examines all possible cutpoints across all predictors at each split; (c) examines all
possible interactions among predictors; and (d) is able
to compensate for missing predictor values without the
need for imputation [19, 21]. It has been widely used to
identify subgroups of individuals who have positive or
negative results from treatment [22–26]. Unlike most
clustering approaches to identifying “hidden” subgroups
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of the data, CART attempts to form subgroups that are
homogeneous with respect to a particular target measure.
CART is a machine-learning method for constructing
prediction models from data, which can be represented
graphically as a tree [27]. In the current study, the end
nodes are groups which have different 6 month observed abstinence rates. The CART tree is obtained by
recursively partitioning data by identifying a predictor
of 6 month observed abstinence and by splitting the
data on a value of that predictor into “left” and “right”
branches. Prediction error is measured in terms of misclassification rate or cost (if there are different costs
associated with different types of misclassification). In
this study, CART was implemented using the R package
RPART [28]. Receiver operating characteristic (ROC)
analysis was used to calculate the ROC area under the
curve (AUC) of the groups. AUC is a measure of the
diagnostic ability of a binary classifier as its discrimination threshold is varied (where such variation alters the sensitivity and specificity of the classifier) [29].
AUC is a general method for assessing any binary classifier. The AUC was validated using fivefold cross validation. Cross validation involved randomly dividing the
set of respondents into five subsets, using one subset
(containing 80% of all observations) to estimate the
algorithm for determining end nodes and the complementary subset (of 20% of all observations) to assess
the percentage correctly classified by those end nodes.
This was repeated five times with the complementary
subsets being nonoverlapping.
Table 1 displays the variables from the regression,
baseline, and 6 month surveys and call completion data
that were used in the CART analysis to predict observed
30 day abstinence at 6 months, with the restriction that
each end node contains 50 or more individuals. We
chose 50 individuals because in our experience, smaller
nodes are insufficiently stable and we wanted a large
enough proportion of participants per node to justify
the effort involved in formulating and implementing a
tailored treatment. The 6 month variables reflected use
of pharmacotherapies anytime from baseline and weight
change from baseline to 6 months.
The predictive ability of the CART tree was assessed
using three separate approaches. First, a logistic regression was performed where the dependent variable was
abstinence at 6 months and the independent variable was
a categorical variable denoting the different end nodes to
establish that the groups were statistically significant predictors of abstinence. Second, a logistic regression [30]
was conducted at each point at which a branch split to
assess the statistical significance of that split. Third, the
percentage of correct classifications and AUC [31] was
calculated for all observations and using fivefold cross
validation [32] to assess the extent to which the identified groups improved the assessment of abstinence. In

addition, separate logistic or linear regressions were
conducted for each of the predictor variable as the dependent variable and a categorical variable denoting the
end nodes as the independent variable to screen the predictors prior to examining them to determine whether
there were potentially clinically important differences between the groups with respect to those predictors.
Cost Effectiveness Analysis
Cost per quitter was calculated for the purpose of
determining groups where changes in treatment might
lead to reduced costs by increasing the percentage
quitting enough to compensate for the costs of additional treatment. To determine the cost per quitter at
6 months, the costs for various treatment components
were estimated, excluding any costs that were only associated with research activities. Labor costs for call minutes were calculated using an average wage of $27.84 per
hour for a health educator (occupational code 21–1091
in May 2016 from BLS.gov) to which was added 25% for
benefits. Call attempts were costed at $1.53 each, letters
sent at $0.49 each, voicemails at $3.06 each, QFL materials at $4.16 per enrollee, and Weight Talk materials at
$8.67 per enrollee. Medications were costed at $18.79 per
week of use, obtained by averaging costs from Costco,
Walmart, and Amazon for 14 or 21 day NRT packages.
We assumed the following: (a) 2 weeks of medication use
for enrollees who were not part of an employer’s program; (b) 4 weeks of medication use for enrollees who
were part of an employer’s program with Optum and
who stated that they had used medication and were not
abstinent at 6 months; and (c) 8 weeks of medication use
for enrollees who were part of an employer’s program
with Optum and who stated that they had used medication and were abstinent at 6 months. The largest cost
components were call attempts, call minutes, and medications, followed by voicemails. QFL materials, Weight
Talk materials, and letters were relatively minor expenses. While costs per enrollee were comparable across
groups, costs per abstainer varied by a factor of more
than 2 ($270 to $629 per abstainer).

Results
CART Tree
Figure 1 contains the CART tree for 30 day observed abstinence at 6 months. The tree contains 10 end nodes,
defined by various splitting variables such as quit confidence. Each end node contains the following information: (a) the number of observations in that end node,
(b) the number of those observations that were either
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Table 1

Variables used in CART analysis as predictors (independent variables)

Source
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35

Variable name, description, and coding

Registration Age (years), height (feet and inches), weight (lbs), BMI (calculated)
Registration Female (coded as 1 = Female, 0 = Other/Missing)
Registration Asthma, coronary artery disease (CAD), chronic obstructive pulmonary disease (COPD), diabetes (each coded as
1 = Yes, 0 = No)
Registration NoChronic. None of 4 listed chronic conditions (coded as 1 = none of asthma, CAD, COPD or diabetes; 0 = at
least one of asthma, CAD, COPD, and/or diabetes)
Registration CPD. Cigarettes per day (count)
Baseline
Race (coded as 1 = White, 2 = Black or African American, 3 = Other)
Baseline
Hispanic (1 = Yes, 0 = No)
Baseline
Education (coded as 1 = <9th grade, 2 = 9–11, HS degree, 3 = some tech, tech/trade degree, 4 = some college, or
5 = college degree)
Baseline
Marital status (coded categorically as 1 = single, 2 = married or living together, 3 = separated, divorced, or widowed)
Baseline
Anxiety. Over the last 2 weeks, how often have you been bothered by feeling nervous, anxious, or on edge? (coded
as 0 = not at all, 1 = several days, 2 = more than half the days, 3 = nearly every day)
Baseline
NoPleasure. Over the last 2 weeks, how often have you been bothered by little interest or pleasure in doing things?
(coded as 0 = not at all, 1 = several days, 2 = more than half the days, 3 = nearly every day)
Baseline
Feeling down. Over the last 2 weeks, how often have you been bothered by feeling down, depressed or hopeless?
(coded as 0 = not at all, 1 = several days, 2 = more than half the days, 3 = nearly every day)
Baseline
Worry. Over the last 2 weeks, how often have you been bothered by not being able to stop or control worrying?
(coded as 0 = not at all, 1 = several days, 2 = more than half the days, 3 = nearly every day)
Baseline
ExerDays. Number of days of moderate to strenuous exercise in the last 7 days
Baseline
ExerMins. Exercise minutes per day (On those days that you engaged in moderate to strenuous exercise, how
many minutes, on average, did you exercise at this level?)
Baseline
ExerTotMins. Calculated total number of exercise minutes per week.
Baseline
Dieting (coded as 1 = not currently dieting, 2 = dieting to lose weight, 3 = dieting to keep weight where it is right now)
Baseline
Medicaid. Medicaid medical insurance (coded as 1 = Yes, 0 = No)
Baseline
WgtGainLikelihood. How likely do you think it is that you will gain weight as a result of quitting/staying quit?
(coded 1 = not at all likely, …, 10 = extremely likely)
Baseline
Motiv. How motivated are you to quit? (coded 1 = low to 10 = high)
Baseline
QuitConf. How confident do you feel that you can quit? (coded 1 = not at all confident, …, 10 = extremely confident)
Baseline
WgtGainConf. How confident are you that you can avoid gaining weight while staying quit? (coded 1 = not at all
confident, …, 10 = extremely confident)
Baseline
WgtGainConc. Concern about gaining weight as a result of quitting (coded 1 = not at all, …, 10 = extremely
concerned)
Baseline
HelpQuit. Thinking about your study group, please rate the degree to which you feel the program will help you
quit smoking. (1 = not at all likely, …, 10 = very high)
6 month
DrugCount. Number of pharmacotherapies used, selected from a list including NRT, nicotine gum, nicotine spray, etc.
6 month
M6_Wgt. Weight at 6 months (lbs)
6 month
M6_WgtGain. Weight change from baseline to 6 months (calculated)
Internal
CommContract. Participant is covered by a commercial contract for smoking cessation services (coded 1 = Yes, 0 = No)
System
Calls
TotTobCalls. Number of completed tobacco calls (count of any planned or ad hoc call that discussed tobacco,
including calls that discussed both tobacco and weight in the simultaneous group)
Calls
TotWgtCalls. Number of completed weight management calls (count of any planned or ad hoc call that discussed
weight, including calls that discussed both tobacco and weight)
Calls
TotTobWgtCalls. Number of completed calls that discussed both tobacco and weight management
Calls
TotControlCalls. Number of completed healthy living calls
Calls
TotCalls. Total number of completed calls. This measure included tobacco or weight calls initiated by the participant and healthy living calls. Calls that discussed both tobacco and weight were counted as two completed calls.
Calls
TotActiveCalls. Total number of completed calls excluding healthy living calls.
Group
Group. Randomization group (coded as 1 = control, 2 = sequential, or 3 = simultaneous)

NRT nicotine replacement therapy.
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QuitConf
TotCalls

HelpQuit
Motiv

Drug Count
Anxiety

CPD

ExerTotMins

# Observations
# with 6m Abstinence
Pct Abstinent at 6m

NoPleasure

162 250 258 171 522 367 317
64
249
168
115
55
69
59
145 131 265
99
99
69
0.278 0.255 0.304 0.435 0.636 0.354 0.305 0.572 0.656 0.702
A

B

C

D

E

F

G

H

I

J

Fig. 1. CART tree for 30 day observed abstinence at 6 months.

abstinent or relapsed (excluding missing values), and (c)
the fraction of nonmissing values for 30 day abstinence
that were abstinent. Out of a total of 2,528 observations
in the tree, 1,106 have values for 30 day abstinence. The
tree also contains the names of the splitting variables.
Ten groups of participants were identified and shown as
Groups A–J. The values defining the splits, the expected
direction for abstainers, and the p-values for each split
are presented in Tables 2.
All of these splits were in the expected direction, with
the exception of more exercise minutes per week being
associated with lower abstinence. Closer examination of
the two groups involved in the split on total exercise minutes suggests that the reason for this is that the group
with fewer exercise minutes per week has a higher prevalence of chronic diseases and generally poorer health.
This split differentiates Group D from E. Even though
these two groups have equal stated high motivation to
quit, the reasons behind that motivation differ (i.e., one
motivated by poor health and the need to quit and the
other by the desire for a healthy lifestyle) and this appears to result in different abstinence rates.
Statistical Significance
The logistic regression for the CART tree as a whole (i.e.,
where the dependent variable is 30 day observed abstinence at 6 months and the independent variable is a categorical variable denoting the end nodes) was statistically
significant at p < .001 (chi-squared [9] = 134.3). The
p-values for logistic regression at each split of the tree are
shown in Table 2. They are all less than .05, and, with one
exception, are all less than .004. To correct for multiple
testing, we also calculated the false discovery rates [33]
and found them all to be <0.05. The percentage classified
correctly using the tree was 66.4% without cross validation

and 61.5% with fivefold cross validation. Cross validation involved randomly dividing the set of respondents
into five subsets, using one subset (containing 80% of all
observations) to estimate the algorithm for determining
end nodes and the complementary subset (of 20% of
all observations) to assess the percentage correctly classified by those end nodes. This was repeated five times
with the complementary subsets being nonoverlapping.
The AUC without cross validation was 0.662 with a 95%
confidence interval (CI) of 0.634 to 0.689. With cross validation, the AUC was 0.615 with a 95% CI of 0.581 to
0.648. Sensitivity (percentage correctly classified among
nonabstainers) and specificity (percentage correctly classified among abstainers) were, respectively, 58.7% and
73.6% without cross classification and 57.0% and 65.6%
with cross validation.

Summary of Differences Between Groups by
Characteristics
Tables 3 shows differences between groups on predictor
variables passing a screen requiring a statistically significant difference between groups. The table also contains response rate and abstinence variables that were
statistically significantly different between groups.
Predictors, response, and abstinence variables are clustered into logical groups, and for each variable, Tables 3
also shows the average response across all respondents
and (if applicable) the odds ratio of that variable with
6 month observed abstinence. Values in the table that
are in bold type face (italic type face) are sufficiently
above (below) the average to be potentially clinically
interesting. There was no difference between groups
in changes in weight or BMI. Table 4 shows treatment
costs.

1038
Table 2
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CART tree splitting information

Splitting variable

Row with definition in Table 1

Values to left

QuitConf

21

<7.5

HelpQuit

24

<6.5

DrugCount

25

<0.5

Values to right

Expected direction for abstainers

p-value *

≥7.5

Right

<.001

≥6.5

Right

.001

≥0.5

Right

.004

Anxiety

10

≥2.5

<2.5

ExerTotMins

16

≥37.5

<37.5

TotCalls

33

<6.5

≥6.5

Right

<.001

Motiv

20

<8.5

≥8.5

Right

<.001

CPD

5

≥19.5

<19.5

11

≥1.5

<1.5

NoPleasure

Right

.001

Left

.043

Left

.004

Right

.003

CPD cigarettes per day.
*The corresponding false discovery rate q-values are all less than 1% except for ExerTotMins, which is less than 5%.

Summary by Group
Below we summarize characteristics by group and specific tailored treatment recommendations:
Group A had below average abstinence rates
across all 6 and 12 month abstinence measures. Their
distinguishing characteristics are low confidence that
they can quit or avoid weight gain, low motivation
to quit, low expectation that the BQS group will help
them to quit, below average exercise, below average
percentage Black, above average commercial contract prevalence, and the highest cost per abstainer.
Participants in this group may need treatment tailored
to build their confidence in quitting, such as practicing
quitting, celebrating successful mini-quits, and eliciting
compelling reasons for quitting to increase their motivation. Encouraging these participants to increase their
physical activity may help them overcome urges and
symptoms of nicotine withdrawal.
Group B had below average 30 day observed abstinence rates but above average response rates, leading to
average missing coded as relapser (MCR) abstinence
rates. Their distinguishing characteristics are their lower
than average prevalence and use of cessation pharmacotherapy at 6 months, racial makeup (higher percentage
White and lower percentage Black), below average confidence that they can quit or avoid weight gain, below
average weight and BMI, and low commercial contract
and Medicaid prevalence. This group had low cost per
enrollee (due to lack of medication) but above average
costs per abstainer (due to low abstinence rates). Tailored
treatment around medication adherence and the importance of using cessation medications and taking all
coaching calls could help boost the quit rates in this
group. This group may need more help identifying and
addressing barriers to using NRT. Focusing on ways to
increase confidence in quitting by experimenting with
mini-quits and breaking the smoking cycle may help.

Group C had below average abstinence rates
across all 6 and 12 month abstinence measures. Their
distinguishing characteristics are above average use of
cessation pharmacotherapy at 6 months, above average
BMI, percentage female, percentage White, frequency
of negative affect (worry, anxiety, lack of pleasure, and
feeling down), Medicaid insurance, chronic obstructive
pulmonary disease (COPD), presence of any of four
chronic diseases, and below average percentage Black,
confidence in ability to quit, commercial contract prevalence, and above average cost per abstainer. Members of
this group may need more help to identify ways to increase their confidence (see above).
Group D had average abstinence rates across all 6
and 12 month abstinence measures. Their distinguishing
characteristics are above average cessation pharmacotherapy prevalence and use, commercial contract prevalence, and exercise (days per week, minutes per day, and
minutes per week) and below average age, percentage female, confidence that they can quit, frequency of negative affect (worry, anxiety, lack of pleasure, and feeling
down), prevalence of Medicaid insurance, and prevalence of COPD or of any of four chronic conditions.
This would appear to be a relatively physically and mentally healthy, young, and employed group. The costs per
abstainer are about average. The quitline appears to be
meeting the needs of this population.
Group E had above average 30 day observed abstinence at 6 months but was about average on the other abstinence measures. Their distinguishing characteristics
were above average cessation pharmacotherapy prevalence and use and below average confidence in quitting
or avoiding weight gain, negative affect measures (worry,
anxiety, and lack of pleasure), and extremely low exercise (days per week, hours per day, and minutes per
week). This may be a group with medical problems
other than COPD, coronary artery disease, diabetes or
asthma, which limit their exercise and result in generally
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Number with observed 6 month abstinence

57.8%
27.8%
12.9%
26.8%
16.1%
22.9%
13.3%

Response rate at 12 months (57.8%, 1.14)

30 day observed abstinence at 6 months (51.4%)

30 day MCR abstinence at 6 months (22.5%)

30 day observed abstinence at 12 months (45.7%, 21.4***)

30 day MCR abstinence at 12 months (26.4%, 11.7***)

90 day observed abstinence at 12 months (38.6%, 27.0***)

90 day MCR abstinence at 12 months (22.3%, 17.0***)

21.9%

30.4%

23.4%

32.6%

21.9%

1.14
76.6%
1.13
4.13
3.90
2.85
1.05
0.58
0.86
36.1%

Number of pharmacotherapies used at 6 months (1.09, 1.06)

Any pharmacotherapy use at 12 months (73.9%, 0.82)

Number of pharmacotherapies used at 12 months (1.03, 0.78**)

Total calls (3.91, 1.09***)

Total active calls (3.82, 1.07***)

Total tobacco calls (2.73, 1.16***)

Total weight calls (1.09, 1.05)

Total combined tobacco and weight calls (0.62, 0.99)

Total control calls (0.79, 1.10**)

Control groupb (33.2%, 1.09)

29.3
186.4
63.1%
76.3%
15.3%

BMI at baseline (30.0, 1.0)

Weight at baseline (189.1, 1.0)

Percentage female (65.8%, 0.92)

Percentage White (67.5%, 0.80)

Percentage Black (26.3%, 1.36*)

15.5%

20.3%

74.1%

80.4%

84.3%
9.4%

57.4%

74.4%
65.6%

29.5
192.4

39.3
31.0

33.3%

0.89

0.61

1.26

2.91

4.17

4.36

1.07

41.4

30.4%

0.67

0.73

1.24

2.51

3.76

3.59

1.00

75.0%

1.43

1.35
77.7%

100%

100%

189.7
179.2

27.8

41.6

20.3%

0.67

0.83

1.56

2.64

4.20

3.95

0.67

41.3%

0.00

0.0%

20.4%

34.7%

25.3%

43.1%

18.5%

43.5%

58.6%

42.6%

69

162

D

25.6%

68.4%

69.6%

190.9

30.5

43.5

33.2%

0.84

0.60

1.21

2.84

4.05

4.92
5.20

Expect BQS group will help quitting (8.36, 1.07***)

Confidence that can quit (7.85, 1.20***)

5.42

8.56

5.34

8.75

5.66

8.56

5.77

8.54

8.82
9.29

8.79

29.8%

66.7%

8.32

24.0%

69.0%

66.1%

187.3

198.0
60.5%

29.7

45.0

29.2%

0.28

0.47

0.61

2.03

2.64

2.40

0.97

68.5%

1.03

80.0%

15.2%

32.5%

18.7%

40.0%

10.5%

30.5%

46.8%

34.5%

59

171

G

31.1

41.0

32.9%

0.20

0.50

0.73

2.05

2.78

2.42

1.02

1.18
4.19

76.3%

0.93

74.5%

14.3%

27.6%

20.2%

38.8%

76.7%

1.44

100%

22.4%

40.6%

25.6%

46.4%

13.6%

35.4%

63.6%
25.2%

51.9%

39.4%

99

258

F

55.2%

39.6%

99

250

E

Confidence and motivation (confidence BQS will help quitting, quit confidence, weight avoidance confidence, motivation to quit)

42.9

Age (43.2 years, 1.0)

Demographics (age, BMI, weight, female gender, White and Black race)

76.5%

Any pharmacotherapy use at 6 months (79.9%, 1.86***)

13.7%

23.4%

16.1%

27.6%

12.5%

30.4%

58.3%

25.5%

41.1%

71.9%

69

168

C

85.9%

55

64

B

Treatment variables: pharmacotherapy use, call completion, and randomization group

46.2%

Response rate at 6 months (43.8%)

Response rate and abstinence

249

Number in group

Number of participants

A

Group designation

Heterogeneity in predictor and abstinence outcomes across groupsa

Characteristic description (study-wide average, odds ratio
[OR] with 30 day abstinence at 6 months)

Table 3

9.28

8.82

24.5%

69.2%

64.8%

186.1

29.4

43.1

32.2%

0.21

0.48

0.69

2.17

2.86

2.52

1.04

73.5%

1.14

81.8%

20.7%

40.1%

24.9%

48.3%

15.9%

57.2%

51.5%

27.8%

145

522

H

9.30

9.13

8.94

34.1%
9.10

59.9%
40.9%

66.2%

192.5

30.8

47.8

41.9%

3.07

1.17

2.43

4.91

7.34

9.05

0.96

74.5%

1.05

81.1%

47.9%

58.2%

52.7%

64.0%

58.7%

70.2%

82.3%

83.6%

265

317

J

52.9%

69.8%

185.5

29.6

43.2

30.8%

0.26

0.45

0.70

2.34

3.04

2.80

1.05

75.5%

1.07

81.1%

22.3%

41.6%

27.2%

50.8%

23.4%

65.6%

53.7%

35.7%

131

367

I
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Continued

7.90

1.39
0.89
0.95

Anxiety (in general) (1.29, 0.82***)

Lack of pleasure (0.91, 0.92)

Feeling down (0.78, 0.90)

1.14

1.15

1.54

1.39

8.61

4.69

B

19.7%
20.3
12.4%
34.1%

Medicaid recipient (23.3%, 1.15)

CPD (20.0, 1.00)

COPD (14.5%, 0.72*)

COPD, diabetes, CHD, or asthma (40.9%, 0.95)

33.4
139

Exercise minutes per day (54.3, 1.00)

Exercise minutes per week (248, 1.00)

281

55.8

1.97

39.1%

17.2%

20.1

10.9%

9.4

249

54.2

1.45
10.8
38

558

39.6%

127.8

31.5%

53.6%

14.8%

19.6

23.6%

14.4

0.60

0.79

0.90

1.06

8.56

4.95

E

3.93

6.2%

22.6%

2.21

19.0

20.3

13.6%

0.53

1.50
20.1

0.66

1.41

34.5%

0.72

8.3

0.83

3.00

8.69

5.45

D

2.34

8.63

5.08

C

269

58.5

2.37

38.4%

12.0%

20.0

25.2%

12.0

0.81

0.98

1.35

1.17

7.28

5.61

F

267

54.4

2.83

51.2%

262

55.8

2.71

41.0%

14.2%

24.6

25.7
21.8%

22.8%

15.5

0.54

0.36

1.13

28.1%

7.0

1.33

2.55

1.81

1.04

9.79
1.87

6.00

9.83

H

5.98

G

268

58.2

2.88

40.2%

12.0%

12.2

23.7%

16.3

0.67

0.85

1.06

1.22

There were no statistically significant differences across groups in the proportion of sequential or simultaneous group members.

250

53.6

2.54

42.6%

15.8%

19.2

24.0%

21.8

0.65

0.86

1.09

1.08

9.03

5.88

6.15
9.82

J

I

Values in bold type face (italic type face) are sufficiently above (below) average with respect to the row variable to be potentially important characteristic of the group.

b

a

*p < .05; **p < .01; ***p < .001.

BQS Best Quit Study, CHD coronary heart disease, COPD chronic obstructive pulmonary disease, CPD cigarettes per day, MCR missing coded as relapser.

1.92

Exercise days per week (2.50, 1.05*)

Exercise

20.1

Commercial contract (15.5%, 1.24)

Health (commercial contract, Medicaid, CPD, COPD, no chronic condition, exercise

1.27

Worry (in general) (1.25, 0.90)

Negative affect (worry, anxiety, lack of pleasure, feeling down)

4.88

Motivation to quit (8.92, 1.31***)

A

Group designation

Confidence that can avoid weight gain (5.61, 1.06*)

Characteristic description (study-wide average, odds ratio
[OR] with 30 day abstinence at 6 months)

Table 3
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Table 4

Average costs per enrollee and per abstainer

Cost component
Call attempts ($ per enrollee)

A

B

C

D

E

F

G

H

I

J

44.95

47.09

45.62

44.78

44.62

47.00

47.74

46.89

47.37

0.22

0.24

0.25

0.19

0.20

0.29

0.28

0.28

0.28

0.04

Voicemails ($ per enrollee)

26.16

26.84

27.18

25.76

26.15

28.27

28.44

28.23

27.86

20.06

Call minutes ($ per enrollee)

Letters ($ per enrollee)

37.49

44.09

46.34

41.89

46.61

45.28

31.15

31.06

31.45

32.78

79.29

QFL materials ($ per enrollee)

4.16

4.16

4.16

4.16

4.16

4.16

4.16

4.16

4.16

4.16

Weight Talk materials ($ per enrollee)

5.54

6.91

6.04

5.78

5.79

5.81

6.13

5.88

6.00

5.03

49.78

0.00

54.16

71.35

71.71

44.23

42.04

54.40

58.39

63.91

174.90

131.58

179.30

198.63

197.91

160.91

159.85

171.29

176.84

209.98

Medications ($ per enrollee)
Total costs ($ per enrollee)
Abstinent rate at 6 months (%)
Total costs ($ per 6 month abstainer)

27.8

25.5

30.4

43.5

63.6

35.4

30.5

57.2

65.6

70.2

629.14

516.00

589.80

456.62

311.18

454.55

524.10

299.46

269.57

299.12

QFL Quit for Life.

increased negative affect. Costs per abstainer were low.
Providing a starter kit of pharmacotherapy appears to
be helping participants to quit. Treatment recommendations include reinforcing the value of pharmacotherapy,
encouraging continued use and providing suggestions
for local sources of low-cost cessation medications.
Discussing mini-quits or relapse prevention strategies
may help boost participants’ confidence in quitting
and staying quit. Encouraging participants to increase
their physical activity may help with their confidence in
quitting without weight gain and improve or alleviate
anxiety and negative affect.
Group F had below average 30 day abstinence at
6 months and below average 90 day abstinence at
12 months. Their distinguishing characteristics were
below average call completion and motivation to quit
and above average weight, BMI, and confidence that they
could quit. Costs per abstainer were average. Tailoring
treatment around medication adherence and the importance of taking all their counseling calls may be needed.
Coaching on ways to boost their confidence and motivation could help members of this group.
Group G had below average 30 day observed and
MCR abstinence at 6 months and below average MCR
abstinence at 12 months. Their distinguishing characteristics were below average response rate at 12 months
(which would have been a contributing factor to their
low MCR abstinence rates at 12 months), call completion, and commercial contract prevalence and above
average confidence and motivation to quit, worry, anxiety, lack of pleasure, frequency of feeling down, CPD,
COPD prevalence, and prevalence of one or more of
four chronic diseases. Costs per abstainer were above
average due to large call minutes. Members of this
group may benefit from tailored coaching about their
depressive symptoms in relation to smoking and nicotine withdrawal and the importance of taking more
coaching calls.

Group H had above average observed abstinence rates
but below average 30 day MCR abstinence at 6 months
(due to the low survey response rate at 12 months). Their
distinguishing characteristics were below average call
completion, low levels of worry, lack of pleasure, or frequency of feeling down and above average confidence
and motivation to quit, and CPD. Costs per abstainer
were below average. Tailored treatment around the importance of taking all counseling calls may be needed.
Group I had above average 30 day observed abstinence at 6 months. Their distinguishing characteristics
were below average call completion, percentage White,
and CPD and above average percentage Black, confidence and motivation to quit, and confidence in avoiding
weight gain. Costs per abstainer were below average.
While the quitline appears to be meeting the needs of
this group, encouraging individuals to take all calls could
boost their quitting skills.
Group J had above average abstinence across all
measures and times. Their distinguishing characteristics
were below average percentage White and above average
call completion, percentage in the control group, percentage Black, confidence in quitting, and prevalence of
commercial contracts. Costs per abstainer were below
average. The quitline appears to be meeting the needs of
this group.

Discussion
We identified 10 distinctive groups from the CART
tree analysis based on 30 day observed abstinence at
6 months post intervention. Groups with low cessation
rates had substantial differences from those with high
cessation rates.
The majority of the variables that we examined as predictors either appeared in the CART tree or were statistically significant predictors of groups in an analysis of
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variance. The only predictors that did not satisfy these
criteria were Hispanic ethnicity, education, marital status,
and whether the participants received weight management counseling. While BMI at baseline and confidence
in avoiding weight gain while staying quit were statistically significant differentiators, other weight-related
variables (amount of weight gain, self-assessed likelihood that the participant will gain weight as a result of
quitting, dieting, and concern about gaining weight as a
result of quitting) were not. This relative lack of weightrelated variables (none of which are tree nodes) suggests
that weight gain may be less important than other factors.
Study participants with low cessation rates (Groups
A–C, F, and G) could be classified as having low confidence in quitting; low outcome expectancies that the
quitline will help them to quit smoking; low use of cessation medications; more anxiety symptoms; and more
physical activity. The group with low abstinence rates
across all abstinence measures (Group A) was characterized by low confidence that they can quit or avoid weight
gain, low motivation to quit, low expectation that the
BQS group will help them to quit, below average exercise, and were less likely to be Black. The group that had
one of the lowest cessation rates (Group B) was characterized by low confidence in quitting or avoiding weight
gain similar to Group A, but this group also had low
use of cessation medications, lower BMI, and a greater
likelihood of being White. This group also had high
rates of response to the 6 month survey and moderate
engagement in counseling. Overall, smokers with low
cessation rates may need more help boosting their confidence in quitting, more cessation medications (or combination pharmacotherapy such as nicotine patch plus
gum or lozenge), and perhaps assistance with stress and
anxiety. Tailored coaching around symptoms of nicotine
withdrawal such as irritability and nervousness could be
helpful.
Study participants with high 30 day cessation rates
(Groups E, H–J) could be classified as having high confidence in quitting and high motivation to quit, and these
cessation rates are similar. Among these groups, Group J
has a substantially higher 90 day cessation rate. Group J
is also characterized by high use of cessation medication
and high call completion. Of the participants with high
cessation rates, this group was the only group who completed more than the average number of calls (tobacco,
weight, control, and total). All other groups had lower
than average calls across all call types. Therefore, while
confidence in quitting and motivation to quit appear sufficient to yield a high 30 day cessation rate, it appears
that the addition of high use of cessation medication
and treatment adherence (i.e., call completion) may be
required to attain high 90 day abstinence.
In summary, confidence in being able to quit is an
important variable, perhaps the most important. Why
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are some people more confident than others? Perhaps
they have tried quitting many times before and have
come close and now believe they can push a little
harder and succeed. Perhaps they are optimists. What
can be done to improve confidence? We also note
that the splitting variable in Fig. 1 after QuitConf is
HelpQuit for individuals with lower confidence in their
ability to quit and TotCalls for those with higher confidence. Quitline assistance appears to make a difference for people with low confidence, but if a person’s
confidence is already high, she also needs adherence
(as measured by more total calls). If the person has
high QuitConf but is not fully following through
(TotCalls <6.5), it seems that motivation really matters, so working on motivation with the quit coaches
would presumably be helpful.
Limitations
Study participants were smokers who were ready to quit
and called state or commercial quitlines for help. The
study sample might not be representative of smokers
who have not sought cessation treatment or those using
other forms of cessation support. However, participants
were similar to the quitline population and, like the general quitline population, utilized only about half of the
standard five-call tobacco cessation calls offered. The
CART groups might have been different with greater
overall call completion. Participant burden related to the
number of proactive calls for treatment and to complete
lengthy follow-up surveys may have impacted willingness
to enroll in the study.
The CART classification tree was developed only
on those individuals who responded to the 6 month
survey, but the tree was applied to all study participants
to examine the characteristics of the groups defined by
the CART tree. Thus, there may be some differences
between the group of individuals used to generate the
CART tree (all of whom have values for abstinence at
6 months) and the individuals used to characterize the
end nodes (some of whom do not have values for abstinence at 6 months). We considered developing the CART
tree based on 30 day MCR abstinence at 6 months, but
that would have relied on the false assumption that
anyone without a 6 month questionnaire was a relapser,
and the tree would be partially attempting to predict
response rate rather than abstinence. In addition, there
was a delay in mailing the 6 month questionnaire to
some respondents, which may be partially responsible
for individuals who did not respond in time (i.e., by the
ninth month). We also considered restricting all analyses just to individuals who responded to the 6 month
survey, but they would not be representative of the
population, would eliminate our ability to calculate the
response rate of each group, and would have reduced
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the sample size for calculating abstinence at 12 months
because there were many participants who did not respond at 6 months but did so at 12 months (as well as
there being respondents at 6 months who did not respond at 12 months).
Another limitation is that data on smoking and
weight were self-reported without verification by direct
objective measurement. Although biochemical validation
of smoking is ideal, self-reported smoking is consistent
with standard measures used telephone-based interventions. Evidence suggests false reporting is minimal for
low-intensity interventions with no face-to-face contact
(the SRNT Subcommittee on Biochemical; An et al.).
Regarding the use of self-reported weight, the literature indicates that people tend to consistently underestimate their weight and their weight gain across time
points, with underestimation disproportionately greater
among the more overweight/obese [34]. To address these
problems, we asked participants their current weight at
baseline and follow-up and use these data to calculate
the weight gain using their self-reported weights. Studies
have shown strong correlations between measured and
self-reported weight indicating that self-reported weight
is an “excellent approximation of actual weight across
a population” [34–36]. In addition, all participants used
self-reporting, so any biases in reporting should affect all
CART groups about equally.
Despite potential limitations, this study addresses
an important public health issue and provides new
data concerning the characteristics that distinguish individuals with successful abstinence at 6 months from
those with unsuccessful abstinence. This study shows
that adding weight control to cessation treatment may
adversely impact short-term quit rates when delivered
concurrently with tobacco treatment via a reduction in
call completion. This trial contributes to the science of
tobacco treatment by describing groups with differential 6 month quit rates among smokers seeking treatment through a telephone tobacco quitline, two-thirds
of whom also received weight management counseling
(either simultaneous with or sequentially after smoking
cessation counseling), and demonstrates the importance of testing efficacious treatments in population
based settings.
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